This was the stock's sixth consecutive day of losses.

Did you analyze how IQVIA Holdings (IQV) fared in its international operations for the quarter ending December 2024? Given the widespread global presence of this clinical testing company, scrutinizing ...

This was the stock's third consecutive day of losses.

IQVIA (NYSE:IQV – Get Free Report) had its price target lifted by Morgan Stanley from $245.00 to $250.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “overweight” ...

IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 12.3% in the 4th quarter, according to the company in its most recent ...

According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual ...

AAM said the report highlights that 90% of the brand biologics scheduled to lose exclusivity in the next 10 years do not have ...

RBC Capital analyst Sean Dodge reiterated a Buy rating on IQVIA Holdings (IQV – Research Report) today and set a price target of $270.00. The ...

In a report released today, Tejas Savant from Morgan Stanley maintained a Buy rating on IQVIA Holdings (IQV – Research Report), with a price ...

According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million.

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution.